Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
stocks
Tesla: Board announces new pay package for CEO Elon Musk
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,028.80 | 106.80 | 1.20% |
CAC 40 | 7,621.04 | 10.97 | -0.14% |
DAX 40 | 23,846.07 | 88.38 | 0.37% |
Dow JONES (US) | 44,161.87 | 11.77 | -0.03% |
FTSE 100 | 9,142.73 | 14.43 | 0.16% |
HKSE | 24,902.53 | 169.08 | 0.68% |
NASDAQ | 20,966.65 | 86.93 | -0.41% |
Nikkei 225 | 40,549.54 | 258.84 | 0.64% |
NZX 50 Index | 12,877.04 | 193.00 | 1.52% |
S&P 500 | 6,309.28 | 20.66 | -0.33% |
S&P/ASX 200 | 8,770.40 | 106.70 | 1.23% |
SSE Composite Index | 3,617.60 | 34.29 | 0.96% |